CGI entered into a research collaboration agreement for the development of molecular testing to facilitate diagnosis, prognosis and management of DLBCL patients. The specimens provided by the investigators will be used for ABC-GCB subtype classification by immunohistochemistry to identify and further validate genomic biomarkers for DLBCL using CGI’s proprietary MatBA®-DLBCL array. CGI also entered into a biological material transfer agreement for the validation of CGI’s proprietary FHACT™ probe in the diagnosis and disease management of head and neck cancers.